Dolutegravir

This is a medication used to treat HIV. It helps your body fight the virus. It's taken as a pill, usually once a day, along with other medicines.

Brand names:Tivicay, Tivicay PD
Medication

What people taking Dolutegravir report

Every report comes from a Lived member, sent anonymously.

Have you tried Dolutegravir for HIV Infection?

NameHow it went

About Dolutegravir

What It's For

Dolutegravir is an HIV medicine sold under the brand name Tivicay, with a version for young children called Tivicay PD that can be dissolved in water. It treats HIV-1, the most common type of HIV, in adults and in children who weigh at least 2 kilograms (about 4.4 pounds). It is always used as part of a combination of HIV medicines, called antiretroviral therapy (ART), because several drugs working together control the virus far better than one alone. It does not cure HIV, but effective treatment helps people with HIV live longer, healthier lives and lowers the risk of passing the virus to others. Dolutegravir belongs to a group called integrase inhibitors. Major US treatment recommendations name it, or the similar drug bictegravir, as the core of the preferred first regimen for most adults with HIV. It also comes built into combination tablets with other HIV medicines: Triumeq (with abacavir and lamivudine), Dovato (with lamivudine alone, a two-drug regimen for adults and adolescents 12 and older who weigh at least 25 kilograms) and Juluca (with rilpivirine, only for adults switching after their virus has been fully controlled on another regimen for at least six months, with no past treatment failure or resistance to either drug). Separately, the CDC lists a dolutegravir-based combination as a preferred option for post-exposure prophylaxis (PEP), a 28-day course started within 72 hours of a possible HIV exposure.

How It Works

HIV infects CD4 cells, a type of white blood cell that helps direct the body's defense against infection. To make new copies of itself, the virus has to insert its genetic material into the DNA of the cell it has infected, a step carried out by a viral enzyme called integrase. Dolutegravir binds to integrase and blocks that insertion, so the infected cell cannot be put to work producing new virus. The other medicines in the regimen block different steps of the virus's life cycle. Attacking several steps at once drives down the amount of virus in the blood (the viral load) and makes it much harder for the virus to develop resistance. As the viral load falls, the number of CD4 cells usually rises, which restores much of the body's ability to fight infections. Because the medicines suppress the virus rather than remove it from the body, treatment continues long term.

Dosage & Administration

For most adults, dolutegravir is one 50-milligram tablet taken once a day, with or without food, together with the other medicines in the regimen. The dose becomes 50 milligrams twice a day when someone also takes certain medicines that speed up its breakdown, such as the tuberculosis antibiotic rifampin, or when the virus already shows resistance to integrase inhibitors. Triumeq and Dovato are each taken as one tablet a day; if an interacting medicine such as rifampin requires twice-daily dolutegravir, the prescriber adds a separate dolutegravir tablet about 12 hours later. Children's doses are based on weight. Tivicay PD tablets can be swallowed whole or fully dispersed in a small amount of drinking water and given within 30 minutes; they should not be chewed, cut or crushed. Tivicay PD and regular Tivicay tablets are not interchangeable milligram for milligram, so a child moving from one to the other needs a new dose from the prescriber. Taking the medicine consistently is what keeps it working. Missed doses can let the virus multiply and develop resistance, which can make this and related drugs less effective. If a dose is forgotten, take it when remembered unless it is nearly time for the next dose, and do not double up; if doses are being missed often, that is worth raising with the care team.

Side Effects

Most people tolerate dolutegravir well. Trouble sleeping, tiredness and headache are the side effects reported most often. In one large trial lasting nearly three years, about 4 in 100 people stopped a dolutegravir regimen because of side effects, compared with 14 in 100 on an older efavirenz-based regimen. Some people gain weight while taking dolutegravir, and the amount varies from person to person, so weight is tracked as part of routine HIV care and any change can be raised with the care team. A small rise in creatinine, a blood test often used to gauge kidney function, is expected in the first month. It reflects a change in how the kidneys release creatinine into the urine rather than kidney damage, and it usually stays stable afterward. Less often, dolutegravir causes an allergic-type reaction (hypersensitivity) that can involve the skin and organs such as the liver. A severe rash, or a rash with fever, unusual tiredness, muscle or joint aches, blisters, peeling skin, mouth sores or red eyes, means stopping the medicine and contacting the prescriber right away, because continuing it can let the reaction become life-threatening. Swelling of the face, lips, tongue or throat, or difficulty breathing or swallowing, needs emergency care by calling 911. Liver injury can also occur, and people with hepatitis B or C are at higher risk; yellow skin or eyes, dark urine, pale stools or pain in the upper right abdomen should be reported to the care team promptly.

Interactions & Warnings

Dolutegravir must not be combined with dofetilide, a heart rhythm medicine, because it raises dofetilide levels enough to cause serious, potentially life-threatening problems. It also raises levels of metformin, a diabetes medicine, so the prescriber may need to review the metformin dose, and of dalfampridine, a multiple sclerosis medicine whose higher levels increase seizure risk. Other medicines can lower dolutegravir levels enough to weaken it. Rifampin, the seizure medicine carbamazepine and some other HIV drugs, such as efavirenz, call for twice-daily dolutegravir. The seizure medicines phenytoin, phenobarbital and oxcarbazepine and the herbal supplement St. John's wort should be avoided. Minerals can bind dolutegravir in the gut and keep it from being absorbed. Take it 2 hours before or 6 hours after antacids or laxatives containing magnesium, aluminum or calcium (such as Tums), sucralfate (an ulcer medicine), buffered medicines (made with an antacid, such as some buffered aspirin), and iron or calcium supplements. Iron or calcium supplements can be taken at the same time as dolutegravir only when both are taken with food. The combination tablets add warnings of their own. Triumeq contains abacavir, which can cause a severe allergic reaction, so a genetic blood test for HLA-B*5701 is done first; people who carry this gene variant should not take it. A reaction can still happen in people without the variant, usually in the first six weeks, and typically combines fever or rash with symptoms such as nausea, vomiting, unusual tiredness, aches or shortness of breath. These mean stopping Triumeq and calling the prescriber right away. After such a reaction, Triumeq or any other medicine containing abacavir or dolutegravir must never be taken again, because restarting can cause a life-threatening reaction within hours. Triumeq and Dovato contain lamivudine, which also acts on the hepatitis B virus, so everyone is tested for hepatitis B before starting. A person who has both infections usually needs added hepatitis B treatment or a different regimen, and stopping lamivudine in someone with hepatitis B can trigger a severe flare of liver inflammation. Juluca also contains rilpivirine, which more medicines can weaken, and adding a dolutegravir tablet does not protect it. Proton pump inhibitors (acid reducers such as omeprazole and pantoprazole), rifampin and the seizure medicines named above must not be used with Juluca. It is taken with a meal, and its timing rules for other acid reducers, antacids and supplements differ from the 2-hour rule above, so anyone on Juluca should go over these with the pharmacist. An early study in Botswana raised concern about neural tube defects (birth defects of the brain and spine) when dolutegravir was taken around conception. Larger later studies in Botswana and Eswatini found rates similar to those with other HIV regimens, although the data are not yet complete enough to rule out every risk. Anyone pregnant or planning a pregnancy should review the regimen with the care team rather than stopping it on their own. Dolutegravir passes into breast milk, and breastfeeding with HIV can pass the virus to the baby, so feeding plans are best made with the care team.

What to Expect

Dolutegravir is meant to be taken every day over the long term. With an effective regimen, most people bring the virus under control within about six months, meaning the viral load falls so low that standard tests cannot detect it. Getting and keeping an undetectable viral load, by taking every dose, protects the person's own health and means HIV is not passed to sexual partners. Regular blood tests track the viral load and CD4 count and check the liver, with more frequent testing at the start and after any change in treatment. In the first weeks to months, as the immune system recovers, some people develop new or worsening symptoms from an infection that was already present, such as tuberculosis. This is called immune reconstitution syndrome, and any new symptoms after starting treatment should be reported so they can be evaluated. If side effects, interactions or other circumstances become a problem, there are other effective regimens to switch to. Pausing or stopping HIV medicine without a plan can let the virus return and develop resistance, so changes are best made with the care team.

Questions to Ask Your Doctor

  1. 1.Is a dolutegravir-based regimen the right choice for me, and would a single combination tablet such as Triumeq or Dovato make sense?
  2. 2.Which of my other medicines and supplements, including antacids, iron, calcium or metformin, need to be timed differently or changed?
  3. 3.How often will my viral load, CD4 count and liver tests be checked, and what results should I expect over the first six months?
  4. 4.What should I do if I miss a dose or am about to run out of medicine?
  5. 5.If I become pregnant or am planning a pregnancy, should anything about my regimen change?

Last reviewed • Oct 2026

Educational content, not medical advice.